Hedeker Wealth’s Adaptive Biotechnologies ADPT Stock Holding History

Hedeker Wealth’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-121,667	Closed	-$1.82M	–	90
2025 Q3	$1.82M	Hold	121,667	–	–	0.38%	60
2025 Q2	$1.42M	Buy	+121,667	New	+$1.11M	0.33%	64
2022 Q3	–	Sell	-121,667	Closed	-$1.06M	–	89
2022 Q2	$1.06M	Buy	+121,667	New	+$1.07M	0.37%	66
2021 Q4	–	Sell	-117,500	Closed	-$3.99M	–	87
2021 Q3	$3.99M	Buy	+117,500	New	+$4.25M	1.23%	29
2021 Q1	–	Sell	-117,500	Closed	-$6.95M	–	66
2020 Q4	$6.95M	Hold	117,500	–	–	2.43%	8
2020 Q3	$5.71M	Hold	117,500	–	–	2.71%	5
2020 Q2	$5.68M	Buy	+117,500	New	+$4.28M	2.93%	4

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Hedeker Wealth's ADPT Position: Q4 2025 in Review

Hedeker Wealth sold out of Adaptive Biotechnologies (ADPT) in Q4 2025, closing a stake of 121,667 shares — an estimated $1.82M sold.

Hedeker Wealth first reported a position in ADPT in Q2 2020 and held it in 7 quarters. The position peaked at $6.95M in Q4 2020. 283 funds tracked by Wall St. Rank hold ADPT as of Q4 2025.

Hedeker Wealth reported no remaining Adaptive Biotechnologies position as of Q4 2025 after selling out during the quarter.
Hedeker Wealth sold 121,667 Adaptive Biotechnologies shares in Q4 2025, an estimated $1.82M.
Hedeker Wealth first reported a position in Adaptive Biotechnologies in Q2 2020 and held it in 7 quarters.
Hedeker Wealth's Adaptive Biotechnologies position peaked at $6.95M in Q4 2020.
283 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2025.

Based on Hedeker Wealth's 13F filing for Q4 2025, filed 23 Jan 2026.